Anti-human immunodeficiency virus type 1 activity of two new nonnucleoside reverse transcriptase inhibitors in combination with other 3 antiretroviral agents in vitro
- VernacularTitle:两种非核苷类逆转录酶抑制剂与已上市药物联合应用的体外抗HIV活性研究
- Author:
Dao-Min, ZHUANG
;
Si-Yang, LIU
;
Ru-Hua, DONG
;
Li, BAI
;
Biao, JIANG
;
Xiao-Long, ZHAO
;
Jing-Yun, LI
- Publication Type:Journal Article
- Keywords:
human immunodeficiency virus;
nonnucleoside reverse transcriptase inhibitors;
drug combination;
synergy;
zidovudine;
efavirenz;
saquinavir
- From:Bulletin of The Academy of Military Medical Sciences
2009;33(6):509-512
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the anti-HIV-1 activity of two new nonnucleoside reverse transcriptase inhibitors (NNRTIs), JB25 and JB26, in combination with 3 approved drugs (AZT, EFV, SQV)in vitro.Methods:The serially diluted 10 concentrations of JB25 and JB26 were combined with 7 serially diluted AZT, EFV and SQV respectively.The combination was added to 384 cell culture plates and then cocultured with HIV-1 ⅢB infected MT-2 cells for 3 days. Finally, the HIV-1 production was determined by measuring the expression of reporter genes of TZM bl cells. The data were analyzed by MacSynergy Ⅱ software.Results:The average capacity of synergism/antagonism of JB25 with AZT, EFV and SQV was 244.45/-5.05(nmol/L)~2%, 119.58/-65.93 (nmol/L)~2% and 145.83/-0.32 (nmol/L)~2% respectively;the average capacity of synergism/antagonism of JB26 with AZT, EFV and SQV was 398.90/0(nmol/L)~2%, 103.62/-0.49(nmol/L)~2% and 138.473/-0.27 (nmol/L)~2% respectively. Conclusion:Two new NNRTIs JB25 and JB26 develop synergism when combined with 3 approved drugs, respectively. MacSynergy Ⅱ software could evaluate the anti-HIV-1 activity of drug combination.
